Atlas Trials

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Clinical trial NCT05669599 · COMPLETED

Trial details

NCT number
NCT05669599
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
ObesityOverweightType 2 Diabetes Mellitus
Start date
2023-01-18
Primary completion
2024-10-08
Enrollment
592

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.